C

Cyclopharm Ltd
ASX:CYC

Watchlist Manager
Cyclopharm Ltd
ASX:CYC
Watchlist
Price: 1.105 AUD -1.34% Market Closed
Market Cap: 122.8m AUD

Cyclopharm Ltd
Investor Relations

Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company provides diagnostic imaging services specializing in lung health. The firm through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. The company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.

Show more
Loading
CYC
S&P/ASX 300
1Y 3Y 5Y 10Y 15Y 20Y

Earnings Calls

No Earnings Calls Available

Management

Mr. James S. McBrayer AIM, BSPharm, F.A.C.I.D., FAICD, GDM
CEO, MD, Company Secretary & Director
No Bio Available
Mr. Mathew Farag
Chief Operating Officer
No Bio Available
Mr. Graham N. Phillips
Finance Manager
No Bio Available
Ms. Sally-Ann Cornelius
Head of Sales
No Bio Available
Ms. Niamh McAree
Head of Quality and Regulatory
No Bio Available
Mr. Chris Quinn
Head of Service
No Bio Available
Ms. Sui Ling Cheah
Financial Controller
No Bio Available
Mr. Lynn McLauchlin
General Manager of Canada
No Bio Available
Mr. Gary T. Somerville
Quality & Regulatory Manager
No Bio Available

Contacts

Address
NEW SOUTH WALES
Unit 4 / 1 The Crescent, Kingsgrove
Contacts
+61295410411.0
www.cyclopharm.com.au
sparklesyt

See Also

Summary
CYC intrinsic value, competitors valuation, and company profile.
DCF Valuation
CYC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CYC stock valuation using valuation multiples.
Wall Street Estimates
CYC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CYC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Back to Top
ALPHA SPREAD
Follow us
Join more than 246,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.